3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Melanoma
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Pancreatic Adenocarcinoma
1
PD-L1-selected Solid Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor, Adult
×
Tiragolumab
×
Clear all
NCT06003621
2024-11-15
MoST-TAP
Omico
Phase 2
Recruiting
96 enrolled